Posted by Michael Wonder on 24 Nov 2016
CADTH issues second final recommendation for Ibrance (palbociclib)
21 November 2016 - CADTH has published a final outcome for palbociclib following a resubmission from Pfizer.
The pERC has recommended the reimbursement of Ibrance, when used in combination with letrozole, for the treatment of post-menopausal women with oestrogen receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
The recommendation is conditional on the reimbursement of palbociclib being improved to an acceptable level which is 'code' for a price reduction.
